Article
Better Responses Observed With Selpercatinib Versus Prior Systemic Therapies for RET+ NSCLC
Rating:
0.0
Views:
110
Likes:
1
Library:
1
Compared with immediate prior therapy, selpercatinib resulted in a greater proportion of objective responses in patients with non–small cell lung cancer whose tumors harbor RET fusions.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value